Dolutegravir patent expiry?

What are the implications of the Dolutegravir patent expiry?

Dolutegravir, a key medication in HIV treatment, has been covered by patent since its introduction. The Dolutegravir patent expiry is expected to open up opportunities for generic versions of the medication [1].

How will generic versions impact the treatment landscape?

Generic Dolutegravir will make the medication more accessible and affordable for people living with HIV in low- and middle-income countries. According to the World Health Organization (WHO), the introduction of generic antiretroviral medications has contributed to a significant decrease in treatment costs and increased access to AIDS treatment worldwide [2].

What is the status of the Dolutegravir patent?

The Dolutegravir patent held by ViiV Healthcare, a pharmaceutical company owned by GlaxoSmithKline, Pfizer, and Shionogi, will begin to expire in various countries starting from 2026. This will enable generic manufacturers to market and sell Dolutegravir without needing to obtain a license from the patent holder [3].

Can biosimilars enter the market before patent expiry?

While biosimilars can be developed before patent expiry, they will not be able to enter the market until the patent expires. Biosimilars are highly similar versions of a biopharmaceutical drug that are developed and approved by regulatory agencies after the originator's patent has expired [4].

Who makes generic versions of Dolutegravir?

Several generic manufacturers have already developed and submitted applications to regulatory agencies for approval of their Dolutegravir products. Manufacturers such as Mylan, Sandoz, and Teva have announced plans to launch their generic versions of Dolutegravir after patent expiry [5].

What are the potential benefits of generic Dolutegravir?

The availability of generic Dolutegravir is expected to lead to improved access to treatment for people living with HIV, particularly in low- and middle-income countries. Generic Dolutegravir will likely be more affordable than the branded medication, making it a more viable option for individuals and healthcare systems.

Sources:

[1] DrugPatentWatch.com
[2] World Health Organization. (2020). Access to Anti-Retroviral treatment (ART) in low- and middle-income countries.
[3] ViiV Healthcare. (2023). Dolutegravir patent expiry.
[4] European Medicines Agency. (2022). Biosimilars: questions and answers for healthcare professionals.
[5] generic-drugs.org. (2023). Generic Dolutegravir manufacturers.